TOKYO, May 28 (Bernama-BUSINESS WIRE) -- Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched “TPD4162F,” a high-voltage intelligent power device (IPD) housed in a small surface mount package, designed to drive motors in products such as air conditioners, air purifiers and pumps. Mass production shipments start today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200527005981/en/ Fabricated with a new process, TPD4162F reduces power dissipation about 10%[1] lower than that of Toshiba’s current IPD, TPD4152F—which will help to lower the power dissipation of devices into which it is integrated. TPD4162F has various control circuits[2], and IGBTs and FRDs are installed on output stage. This supports direct drive of a brushless DC motor with square wave input signals from either a Hall sensor or a Hall IC without requiring a PWM controller IC. Various built-in protection circuits[3] reduce the peripheral circuit count. Use of a small surface mount package, HSSOP31, can help reduce the size and height of motor control boards. Applications Brushless DC motors for home appliances equipment • Fan motors (air conditioners, air purifiers, ventilation fans and ceiling fans, etc.) • Pumps Features • High voltage: Power supply voltage (VBB)=600V • Low loss: Output saturation voltage rating (VCEsat)=2.0V (typ.) @IC=0.5A FRD forward voltage (VF)=1.5V (typ.) @IF=0.5A •Small and thin HSSOP31 package: 17.5x11.9mm (typ.), t=2.2mm(max) Main Specifications Please click here Notes: [1] As of May 2020, values measured by Toshiba. (Test condition: VBB=280V, VCC=15V, VSP=4V, fs=20kHz, Ta=25℃, Pin=40W, No-fan, Heat sink less) [2] PWM circuit, 3-phase decode circuit, level shift high-side driver circuit, low-side driver circuit [3] Current limit, over current protection circuits, thermal shutdown circuits, under voltage protection circuits Follow the link below for more on the new product. TPD4162F https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TPD4162F Follow the link below for more on Toshiba Intelligent Power IC line-up. Intelligent Power IC https://toshiba.semicon-storage.com/ap-en/semiconductor/product/intelligent-power-ics.html To check availability of the new products at online distributors, please visit: https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TPD4162F.html Reference Design https://toshiba.semicon-storage.com/ap-en/semiconductor/design-development/referencedesign/articles/tpd4162fsquare-wave-control-type-bldc-motor-drive-circuit_motorcontrol_rd043.html *Company names, product names, and service names may be trademarks of their respective companies. Customer Inquiries: Power Device Sales & Marketing Department Tel: +81-3-3457-3933 https://toshiba.semicon-storage.com/ap-en/contact.html Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice. http://mrem.bernama.com/viewsm.php?idm=37439 Pivotal Preclinical Oncology Platform Expands To Include New Patient-Derived Organoid Models28/5/2020
SAN DIEGO, May 27 (Bernama-GLOBE NEWSWIRE) -- Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht Organoid Technology (HUB) patient-derived organoids (PDO). This marks a significant milestone in the development of CrownBio’s innovative organoid platform and the first, large-scale commercial availability of HUB PDO for oncology drug discovery services.
Organoid technologies are transforming oncology drug development and disrupting the traditionally followed workflows. CrownBio holds an exclusive license from HUB to provide preclinical oncology drug development and validation services using world-leading HUB Organoid Technology, originally developed by the Clevers lab. “Organoid models will revolutionize the way preclinical oncology research is performed,” said Henry Li, PhD, chief scientific officer at CrownBio. “Using organoids, drug screening will evolve from current linear workflows to a matrixed high throughput screening approach, allowing lead candidates to be tested simultaneously across multiple patient populations in an easily scalable and clinically-relevant model system.” The newly available models join CrownBio’s established and ever-expanding platform of PDX-derived organoids (PDXO). PDXO are generated using HUB protocols to derive tumor organoids from CrownBio’s PDX collection, which is the world’s largest commercially available panel of PDX. The complementary panels of patient and PDX-derived organoids, alongside parental PDX models, provide the opportunity to change the way drug discovery is conducted. The combined collection of in vitro and in vivo patient-derived models are clinically relevant and predictive, and the matched model pairs offer a more efficient and informed transition from in vitro to in vivo studies to help reduce the currently high attrition rates of anticancer agents. “I am delighted to see the HUB Organoid biobank becoming available to the wider research community for oncology drug discovery,” said Rob Vries, PhD, chief executive officer of HUB. “Our partnership with CrownBio is continuing to equip pharmaceutical and biotech companies with the cutting-edge models needed to transform their anticancer agent development programs.” Benefits of the newly available PDO models include the availability of non-malignant, healthy tissue-derived organoids. This enables PDO studies to be well controlled for studying compound toxicity and therapeutic windows, including matched tissue controls. The new models cover the important indications of breast, colon, lung, and pancreatic cancer and are directly derived from European patients. The collection includes PDO from primary and metastatic lesions, multiple lesions from the same patient to capture intra-patient heterogeneity, as well as both healthy and tumor organoids. CrownBio’s organoid platform is available to clients globally. The newly acquired PDO models have completed transfer to CrownBio. They are available for client studies immediately for efficacy and potency evaluation, combination strategy optimization, and lead candidate selection. http://mrem.bernama.com/viewsm.php?idm=37431 KUALA LUMPUR, May 21 -- China Mobile International, Facebook, MTN GlobalConnect, Orange, stc, Telecom Egypt, Vodafone and WIOCC will partner to build 2Africa, the most comprehensive subsea cable to serve the African continent and Middle East region. It will also connect via east Africa with other subsea cables for expanded connectivity to Asia. The parties have appointed Alcatel Submarine Networks (ASN) to build the cable in a fully funded project which will greatly enhance connectivity across Africa and the Middle East. At 37,000km long, 2Africa will be one of the world’s largest subsea cable projects and interconnect Europe (eastward via Egypt), the Middle East (via Saudi Arabia) and 21 landings in 16 countries in Africa. The system is expected to go live in 2023/4, delivering more than the total combined capacity of all subsea cables serving Africa today, with a design capacity of up to 180Tbps on key parts of the system. It will deliver much needed Internet capacity and reliability across large parts of Africa, supplement the fast-growing capacity demand in the Middle East and underpin the further growth of 4G, 5G and fixed broadband access for hundreds of millions of people. In countries where the 2Africa cable will land, service providers will obtain capacity in carrier-neutral data centres or open-access cable landing stations on a fair and equitable basis, supporting healthy Internet ecosystem development by facilitating greatly improved accessibility for businesses and consumers alike. The 2Africa cable has been designed to improve resilience and maximise performance, including the option of a seamless optical crossing between East Africa and Europe, according to a statement. More details at www.2AfricaCable.com. -- BERNAMA |
Archives
October 2023
Categories |